1,721,305 research outputs found
Impact of comorbidity on the risk and cost of hospitalization in HIV-infected patients: real-world data from Abruzzo Region [Corrigendum]
No full textCammarota S, Citarella A, Manzoli L, Flacco ME, Parruti G. Clinicoecon Outcomes Res. 2018;10:389–398. Page 393, Table 2, CCI scorec (vs 0), ≥2 row, the values for the Unadjusted IRR and Adjusted IRR columns are incorrect, the data “2.32 (1.79–3.01)” should read “2.87 (2.22–3.72)” and “2.04 (1.56–2.66)” should read “2.43 (1.86–3.17)”. Read the original article 
Letter by Santilli et al regarding article, "Traditional risk factors are not major contributors to the variance in carotid intima-media thickness".
No full textComparative analysis of beta-adrenergic receptor kinase and beta-arrestin mRNA expression in human cells.
No full textReceptor phosphorylation is a key step in the process of rapid desensitization. beta-Adrenergic receptor kinase is a specific receptor kinase that is known to phosphorylate and induce desensitization of several G-coupled synaptic receptors only when they are occupied by their agonists. We recently cloned human beta ARK cDNA and reported high levels of beta ARK expression in human peripheral blood leukocytes, also providing the first evidence for its possible functional role in these cells. Complete homologous receptor desensitization by beta ARK requires an additional cytosolic factor, called beta-arrestin. In the present study, we have cloned a 212 bp fragment of the human beta-arrestin cDNA to perform a comparative analysis of beta ARK and beta-arrestin mRNA expression in various human cell types. We found that also beta-arrestin mRNA is abundant in non-innervated tissues and cells. The fact that the entire machinery for G-coupled receptor desensitization is highly expressed in these cells further supports the idea that beta ARK may regulate nonsynaptic as well as synaptic receptors
Molecular cloning, functional expression and mRNA analysis of human beta-adrenergic receptor kinase 2.
No full textIn the present study the cDNA of human beta ARK2 was cloned using both PCR and cDNA library screening, subcloned into an expression vector and transiently expressed in COS7 cells. The expressed kinase activity was approximately 40% as efficient as human beta ARK1 in phosphorylating bovine rod outer segments in vitro. Northern blot analysis of human and bovine mRNA revealed a species-specific pattern of multiple hybridization bands, with two major transcripts in human rather than one in bovine. High levels of mRNA expression were found in peripheral blood leukocytes
Efficacy of 1998 Vs 2006 First-Line Antiretroviral Regimens for HIV Infection: An Ordinary Clinics Retrospective Investigation
No full textPurpose: The evidence suggesting increased HAART efficacy over time comes from randomized trials or cohort
studies. This retrospective multicenter survey aimed to assess the variation over time in the efficacy and tolerability
of first-line HAART regimens in unselected patients treated in ordinary clinical settings.
Methods: Retrospective analysis of data of all patients starting first-line HAART regimens in 1998 and 2006 at
adhering centers in the Italian CISAI group.
Results: For the 543 patients included, mean age was 39.1 ± 9.8y in 1998 and 41.0 ± 10.7y in 2006 (p=0.03),
with a similar proportion of males. Baseline mean log10 HIV-RNA was 4.56 ± 0.97 copies/mL in 1998 vs 4.91 ± 0.96
copies/mL in 2006 (p<0.001); baseline mean CD4 T-cell counts were 343 ± 314/mm3 in 1998 vs 244 ± 174/mm3 in
2006 (p<0.001). The following outcomes were significantly improved at 48w in 2006: proportion with undetectable
HIV-RNA (86.3% vs 58.0%; p<0.001); mean increase in CD4 T-cells count (252 ± 225 vs 173 ± 246; p<0.001);
HAART modification (20.1% vs 29.2%; p=0.02); HAART interruption (7.3% vs 14.6%; p=0.01); proportion reporting
optimal adherence (92.2% vs 82.7%, p=0.03). No differences were observed in the prevalence of grade 3-4 WHO
toxicities (26.4% vs 26.6%; p=0.9). Multivariate logistic regression showed that being treated in 1998 remained an
independent predictor of virological failure after several adjustments, including adherence.
Conclusions: Our data from patients not included in clinical trials or cohort studies provide an additional
line of evidence that the effectiveness of HAART significantly improved in 2006. Treated patients, however, were
significantly older and more frequently late HIV presenters in 2006 than in 1998
Rhodopsin phosphorylation by transiently expressed human beta ARK1: a new method for drug development.
No full textLa dimensione operativa psicologico-clinica nell’ambito dell’infettivologia ospedaliera.
No full textRegulation of G protein-coupled receptor kinase subtypes in activated T lymphocytes. Selective increase of beta-adrenergic receptor kinase 1 and 2.
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
- …
